reports
Cardiff Oncology to Participate in Three Upcoming Investor Conferences...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Interested part...
Cardiff Oncology Reports Full Year 2025 Results and Provides Business ...
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Hea...
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Monday,...
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare ...
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026. Details of the presentation can be found below. Presenter: Mani Mohindru, PhD (...
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Off...
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. “It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an extraordinary track r...
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment ...
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”). “We would like...
Cardiff Oncology Announces Positive Update from its Randomized Phase 2...
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naï...
Cardiff Oncology Announces Executive Leadership Changes as it Transiti...
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company’s next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned b...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Progr...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts – Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored T...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phas...
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conf...
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM ET Interested pa...
- Jonathan Moreland
ALLE ALLEGION PLC
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SHBI SHORE BANCSHARES INC.
RPD RAPID7 INC.
NWBI NORTHWEST BANCSHARES INC.
HOO HERBALIFE NUTRITION LTD.
CALX CALIX NETWORKS
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
AP AMPCO-PITTSBURGH
GBLI GLOBAL INDEMNITY PLC
MSBI MIDLAND STATES BANCORP
INSE INSPIRED ENTERTAINMENT
WMG WARNER MUSIC GROUP CORP.
PMTS CPI CARD GROUP
BHC BAUSCH HEALTH COMPANIES INC.
VRCA VERRICA PHARMACEUTICALS
ESTC ELASTIC N.V.
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
TBTC INC.
VLA TABLE TRAC INC.
ONEW ARBOR METALS
ABCL ONEWATER MARINE
ALIT ABCELLERA BIOLOGICS
BMEA ALIGHT
PBBK INC. / DELAWARE
NRDY BIOMEA FUSION
OWL INC.
ENOV PB BANKSHARES
QDEL INC.
J NERDY INC.
MAIA BLUE OWL CAPITAL INC
SMRT ENOVIS CORPORATION
FISV QUIDEL CORP
PODC JACOBS SOLUTIONS INC.
GAM MAIA BIOTECHNOLOGY INC
NUTX SMARTRENT INC
BAER FISERV
TENX INC.
SGI COURTSIDE GROUP INC.
AFCG GENERAL DE ALQUILER DE MAQUINARIA
DSM NUTEX HEALTH INC
XELB WILDFIRE NEW PUBCO
ANNX INC.
KTTA TENAX THERAPEUTICS INC.
SOMNIGROUP INTERNATIONAL INC.
AFC GAMMA
INC.
DREYFUS STRATEGIC MUNICIPAL BOND FUND
INC.
XCEL BRANDS INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
PASITHEA THERAPEUTICS CORP
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SLGN SILGAN HOLDINGS INC.
RPD RAPID7 INC.
OPK OPKO HEALTH INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
GBCI GLACIER BANCORP INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FOXF FOX FACTORY HOLDING CORP.
EIG EMPLOYERS HOLDINGS INC.
ARCC ARES CAPITAL CORPORATION
RLMD RELMADA THERAPEUTICS
TREX TREX COMPANY INC.
VVV VALVOLINE INC.
KREF KKR REAL ESTATE FINANCE TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
SONO SONOS
VRCA VERRICA PHARMACEUTICALS
AMCR AMCOR PLC
AVTR AVANTOR
TSLX INC.
VLA SIXTH STREET SPECIALTY LENDING
MRVI INC.
FRSH ARBOR METALS
SG MARAVAI LIFESCIENCES HOLDINGS
TBBK FRESHWORKS INC.
QDEL SWEETGREEN INC
BHVN THE BANCORP
WEST INC.
SMRT QUIDEL CORP
CRVO BIOHAVEN LTD
NCDL WESTROCK COFFEE COMPANY LLC
GAM SMARTRENT INC
STRZ CERVOMED INC
GMRE NUVEEN CHURCHILL DIRECT LENDING CORP
OESX GENERAL DE ALQUILER DE MAQUINARIA
STARZ ENTERTAINMENT CORP
GLOBAL MEDICAL REIT INC.
ORION ENERGY SYSTEMS INC
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
RIGN TRANSOCEAN LTD.
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VRCA VERRICA PHARMACEUTICALS
AEYE AUDIOEYE INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
UTZ UTZ BRANDS INC (A)
ABCL ABCELLERA BIOLOGICS
PBBK PB BANKSHARES
NEXT INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
ENOV EVOLV TECHNOLOGIES HLDGS INC
QDEL ENOVIS CORPORATION
J QUIDEL CORP
EBC JACOBS SOLUTIONS INC.
WEST EASTERN BANKSHARES INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
MNR GRAN TIERRA ENERGY INC.
GAM MACH NATURAL RESOURCES LP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
GF SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
POST POST HOLDINGS INC.
NWBI NORTHWEST BANCSHARES INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GLP GLOBAL PARTNERS LP
CALX CALIX NETWORKS
GAM GENERAL AMERICAN INVESTORS CO. INC.
PBI PITNEY BOWES INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
PED PEDEVCO CORP
VRCA VERRICA PHARMACEUTICALS
ONEW ONEWATER MARINE
BBWI BATH & BODY WORKS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
QDEL QUIDEL CORP
J JACOBS SOLUTIONS INC.
EBC EASTERN BANKSHARES INC
SMRT SMARTRENT INC
GTE GRAN TIERRA ENERGY INC.
MNR MACH NATURAL RESOURCES LP
RMI RIVERNORTH OPPOR MUN INC FD INC
Verrica Pharmaceuticals Announces Private Placement Financing of $50 M...
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica’s Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company ...
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcar...
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December 2-4, 2025. Details of the presentation can be found below. Presenters: Mark Erlander, PhD (CEO) Date: 12/02/2025...
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results – Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH...
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 C...
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting – Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315’s ...
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Busin...
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to de...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.